Expression of miRNA-630 in bladder urothelial carcinoma and its clinical significance.
- Author:
Zhi-Yu WANG
1
;
Wei ZHANG
2
;
Jin-Jian YANG
3
;
Dong-Kui SONG
3
;
Jin-Xing WEI
3
Author Information
1. Department of Urology, the First Affiliated Hospital, Zhengzhou University, Zhengzhou, 450000, China. yuzhi525@163.com.
2. Department of Pharmacy, Zhengzhou Orthopaedics Hospital, Zhengzhou, 450000, China.
3. Department of Urology, the First Affiliated Hospital, Zhengzhou University, Zhengzhou, 450000, China.
- Publication Type:Journal Article
- Keywords:
disease-free survival;
miR-630;
overall survival;
prognosis;
urothelial carcinoma
- MeSH:
Adult;
Aged;
Biomarkers, Tumor;
biosynthesis;
genetics;
Carcinoma;
genetics;
pathology;
Disease-Free Survival;
Female;
Gene Expression Regulation, Neoplastic;
Humans;
Kaplan-Meier Estimate;
Male;
MicroRNAs;
biosynthesis;
genetics;
Middle Aged;
Neoplasm Staging;
Prognosis;
Urinary Bladder Neoplasms;
genetics;
pathology;
Urothelium;
pathology
- From:
Journal of Huazhong University of Science and Technology (Medical Sciences)
2016;36(5):705-709
- CountryChina
- Language:English
-
Abstract:
Many studies informed that microRNAs (miRNAs) could function as diagnostic and prognostic indicators in several cancers. The aims of this study were to explore the expression of miR-630 in bladder urothelial carcinoma and its clinical significance for the evaluation of cancer prognosis. A total of 116 patients with bladder urothelial carcinoma were obtained in this retrospective study between May, 2012 and Sep. 2015. Quantitative real-time PCR (qRT-PCR) was conducted to evaluate the expression level of miR-630. The chi-square test was used to examine the associations between miR-630 expression and the clinicopathological features. The Kaplan-Meier method was conducted to explore the survival status of urothelial carcinoma patients. The log-rank test was used to analyze differences in survival rate. The results showed an obvious increase in miR-630 expression from normal bladder to bladder urothelial carcinoma (P=0.027). Additionally, patients with higher miR-630 expression had significantly shorter disease-free survival (DFS) (P=0.043) and overall survival (OS) (P=0.038) than those with lower miR-630 expression. Furthermore, multivariate analysis revealed that up-regulation of miR-630 was an independent prognostic factor for both DFS (P=0.042) and OS (P=0.046). It was demonstrated that miR-630 may be a novel and valuable prognostic factor for bladder urothelial carcinoma.
